Powder: -20°C for 3 years | In solvent: -80°C for 1 year
YKL-05-099 是盐诱导型激酶 (SIK) 抑制剂。能够抑制SIK1(IC50:10 nM)、SIK3(IC50:30 nM)的活性,对SIK2(IC50:40 nM) 的活性抑制作用稍弱。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 547 | 现货 | ||
5 mg | ¥ 2,320 | 现货 | ||
10 mg | ¥ 3,730 | 现货 | ||
25 mg | ¥ 5,900 | 现货 | ||
50 mg | ¥ 8,320 | 现货 | ||
100 mg | ¥ 11,200 | 现货 | ||
500 mg | ¥ 22,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,970 | 现货 |
产品描述 | YKL-05-099 is an inhibitor of the salt-inducible kinase(SIK1 and SIK3 ; IC50s: 10 and 30 nM, respectively). It has a slightly less potent SIK2-inhibitory (IC50:40 nM). |
靶点活性 | SIK1:10 nM, SIK2:40 nM, SIK3:30 nM |
体外活性 | YKL-05-099 inhibits the production of the inflammatory cytokines TNFα, IL-6 and IL-12p40, and only modestly enhances IL-1β release in BMDCs stimulated with the yeast cell wall extract Zymosan A. YKL-05-099 has slightly less potent SIK2-inhibitory (IC50=40 nM) and IL-10-enhancing activities (EC50=460 nM). YKL-05-099 binds to SIK1 and SIK3 (IC50s: 10 and 30 nM, respectively, in a competitive binding assay). Preincubating bone marrow-derived macrophages with YKL-05-099 decreases LPS stimulated phosphorylation of HDAC5 at the SIK-specific phosphorylation site Ser259 [1]. |
体内活性 | YKL-05-099 is highly soluble (PBS solubility=428 μM) and present in an unbound state at appreciable levels in mouse plasma. YKL-05-099 is non-toxic at concentrations of less than 10 μM and stable in mouse liver microsomes for more than 2 hours. YKL-05-099 dose-dependently decreases the abundance of TNFα in serum beginning at 5 mg/Kg and increases IL-10 levels at the 20 mg/Kg dose by more than 2-fold. YKL-05-099 dose-dependently decreases phosphorylation of HDAC5 at the SIK-regulated site Ser259; reduced phosphorylation is observed at the lowest dose (5 mg/Kg) and is below the limit of detection by immunoblotting beginning at the 20 mg/Kg dose [1]. |
分子量 | 600.11 |
分子式 | C32H34ClN7O3 |
CAS No. | 1936529-65-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 75 mg/mL (124.98 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.6664 mL | 8.3318 mL | 16.6636 mL | 41.659 mL |
5 mM | 0.3333 mL | 1.6664 mL | 3.3327 mL | 8.3318 mL | |
10 mM | 0.1666 mL | 0.8332 mL | 1.6664 mL | 4.1659 mL | |
20 mM | 0.0833 mL | 0.4166 mL | 0.8332 mL | 2.083 mL | |
50 mM | 0.0333 mL | 0.1666 mL | 0.3333 mL | 0.8332 mL | |
100 mM | 0.0167 mL | 0.0833 mL | 0.1666 mL | 0.4166 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
YKL-05-099 1936529-65-5 PI3K/Akt/mTOR signaling SIK YKL05099 YKL 05 099 inhibit Salt-inducible Kinase (SIK) Inhibitor inhibitor